These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25442003)

  • 21. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
    Barnum CJ; Eskow KL; Dupre K; Blandino P; Deak T; Bishop C
    Neuroscience; 2008 Sep; 156(1):30-41. PubMed ID: 18687386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
    Thornton E; Hassall MM; Corrigan F; Vink R
    Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
    Padovan-Neto FE; Cavalcanti-Kiwiatkoviski R; Carolino RO; Anselmo-Franci J; Del Bel E
    Neuropharmacology; 2015 Feb; 89():87-99. PubMed ID: 25196732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
    Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
    Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
    Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L; Robitaille C; Lebel M; Cyr M
    Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
    Lundblad M; Vaudano E; Cenci MA
    J Neurochem; 2003 Mar; 84(6):1398-410. PubMed ID: 12614340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
    Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression.
    Feyder M; Södersten E; Santini E; Vialou V; LaPlant Q; Watts EL; Spigolon G; Hansen K; Caboche J; Nestler EJ; Fisone G
    Biol Psychiatry; 2016 Mar; 79(5):362-371. PubMed ID: 25193242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
    Xie CL; Wang WW; Zhang SF; Yuan ML; Che JY; Gan J; Song L; Yuan WE; Liu ZG
    Sci Rep; 2014 Dec; 4():7506. PubMed ID: 25511986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC; Varney MA; Newman-Tancredi A
    Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
    J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
    Zhang ZR; Zhang XR; Luan XQ; Wang XS; Wang WW; Wang XY; Shao B; Xie CL
    Neurochem Int; 2019 Dec; 131():104543. PubMed ID: 31491493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
    Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
    J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.